Search details
1.
Sintilimab Plus Modified FOLFIRINOX in Metastatic or Recurrent Pancreatic Cancer: The Randomized Phase II CISPD3 Trial.
Ann Surg Oncol
; 30(8): 5071-5080, 2023 Aug.
Article
in English
| MEDLINE | ID: mdl-37052821
2.
Construction of TME and Identification of crosstalk between malignant cells and macrophages by SPP1 in hepatocellular carcinoma.
Cancer Immunol Immunother
; 71(1): 121-136, 2022 Jan.
Article
in English
| MEDLINE | ID: mdl-34028567
3.
Comprehensive Clinical Analysis of Gallbladder Neuroendocrine Neoplasms: A Large-Volume Multicenter Study During One Decade.
Ann Surg Oncol
; 29(12): 7619-7630, 2022 Nov.
Article
in English
| MEDLINE | ID: mdl-35849293
4.
Dynamic alterations of genome and transcriptome in KRAS G13D mutant CRC PDX model treated with cetuximab.
BMC Cancer
; 20(1): 416, 2020 May 13.
Article
in English
| MEDLINE | ID: mdl-32404198
5.
The efficacy and toxicity of chemotherapy in the elderly with advanced pancreatic cancer.
Pancreatology
; 20(1): 95-100, 2020 Jan.
Article
in English
| MEDLINE | ID: mdl-31786057
6.
Nutrition and metabolism status alteration in advanced hepatocellular carcinoma patients treated with anti-PD-1 immunotherapy.
Support Care Cancer
; 28(11): 5569-5579, 2020 Nov.
Article
in English
| MEDLINE | ID: mdl-32361828
7.
Neoadjuvant chemotherapy for primary resectable pancreatic cancer: a systematic review and meta-analysis.
HPB (Oxford)
; 22(6): 821-832, 2020 06.
Article
in English
| MEDLINE | ID: mdl-32001139
8.
Integrated multiomic analysis reveals comprehensive tumour heterogeneity and novel immunophenotypic classification in hepatocellular carcinomas.
Gut
; 68(11): 2019-2031, 2019 11.
Article
in English
| MEDLINE | ID: mdl-31227589
9.
Tumour cell-derived debris and IgG synergistically promote metastasis of pancreatic cancer by inducing inflammation via tumour-associated macrophages.
Br J Cancer
; 121(9): 786-795, 2019 10.
Article
in English
| MEDLINE | ID: mdl-31588122
10.
Hypoxia-inducible factor-1α/interleukin-1ß signaling enhances hepatoma epithelial-mesenchymal transition through macrophages in a hypoxic-inflammatory microenvironment.
Hepatology
; 67(5): 1872-1889, 2018 05.
Article
in English
| MEDLINE | ID: mdl-29171040
11.
ASO Visual Abstract: Sintilimab Plus Modified FOLFIRINOX in Metastatic or Recurrent Pancreatic Cancer: The Randomized Phase II CISPD3 Trial.
Ann Surg Oncol
; 30(8): 5081-5082, 2023 Aug.
Article
in English
| MEDLINE | ID: mdl-37225831
12.
Combination of transarterial chemoembolization and sorafenib improves outcomes of unresectable hepatocellular carcinoma: an updated systematic review and meta-analysis.
Jpn J Clin Oncol
; 48(12): 1058-1069, 2018 Dec 01.
Article
in English
| MEDLINE | ID: mdl-30272196
13.
Hypoxia-inducible factor-2α promotes tumor progression and has crosstalk with Wnt/ß-catenin signaling in pancreatic cancer.
Mol Cancer
; 16(1): 119, 2017 07 14.
Article
in English
| MEDLINE | ID: mdl-28705232
14.
Hook1 inhibits malignancy and epithelial-mesenchymal transition in hepatocellular carcinoma.
Tumour Biol
; 39(7): 1010428317711098, 2017 Jul.
Article
in English
| MEDLINE | ID: mdl-28718370
15.
LB-100 sensitizes hepatocellular carcinoma cells to the effects of sorafenib during hypoxia by activation of Smad3 phosphorylation.
Tumour Biol
; 37(6): 7277-86, 2016 Jun.
Article
in English
| MEDLINE | ID: mdl-26666823
16.
Optimizing hepatocellular carcinoma disease staging systems by incorporating tumor micronecrosis: A multi-institutional retrospective study.
Cancer Lett
; 585: 216654, 2024 Mar 31.
Article
in English
| MEDLINE | ID: mdl-38272344
17.
Case Report: Partial response to single-agent pembrolizumab in a chemotherapy-resistant metastatic pancreatic cancer patient with a high tumor mutation burden.
Front Oncol
; 13: 1118633, 2023.
Article
in English
| MEDLINE | ID: mdl-36937383
18.
Oxaliplatin plus irinotecan vs irinotecan as second-line treatment in pancreatic cancer patients: a randomized-controlled open-label Phase II study.
Gastroenterol Rep (Oxf)
; 11: goac088, 2023.
Article
in English
| MEDLINE | ID: mdl-36751477
19.
An immunometabolism subtyping system identifies S100A9+ macrophage as an immune therapeutic target in colorectal cancer based on multiomics analysis.
Cell Rep Med
; 4(4): 100987, 2023 04 18.
Article
in English
| MEDLINE | ID: mdl-36990096
20.
RUNX-3-expressing CAR T cells targeting glypican-3 in patients with heavily pretreated advanced hepatocellular carcinoma: a phase I trial.
EClinicalMedicine
; 63: 102175, 2023 Sep.
Article
in English
| MEDLINE | ID: mdl-37680942